First patient dosed with ADC therapy designed to disrupt tumor blood supply
Angiex has announced the beginning of the first-in-human trial of AGX101, an antibody-drug conjugate (ADC) treatment that targets solid tumors with a unique mode of action.
Archives for August 13, 2024
FDA approves Galderma’s Nemluvio for chronic skin condition
The US approval of Nemluvio marks a major milestone for Galderma, a Swiss company developing treatments for a wide range of conditions affecting the skin.
Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer
The FDA has given the green light to Lymphir, the first immunotherapy for the treatment of cutaneous T-cell lymphoma (CTCL) to get approval in over five years.
How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies
Driven by personal loss and inspired by the progress in disease management, Elaine has dedicated more than 20 years to the clinical trial technology industry.